Heat Biologics Inc
HTBX
Get informed when a big investor buys or sells
+ FollowMarket Cap$61.07M
Close$
$2.70
13.5% upside
Current Fair Value
13.5% upsideUndervalued by 13.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $61.07 Million |
|---|---|
| Enterprise Value | $19.15 Trillion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.41 |
| Beta | 0.3 |
| Outstanding Shares | 61,143,000 |
Return
| Return on Equity | 3654.00% |
|---|---|
| Return on Assets | -233.92% |
| Return on Invested Capital | 3037.18% |
Valuation & Multiples
| P/E Ratio | 0 |
|---|---|
| PEG | 0 |
| Price to Sales | 0.0 |
| Price to Book Ratio | -0.0 |
| Enterprise Value to Revenue | 2.77 |
| Enterprise Value to EBIT | -0.44 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 1.03 |
| Debt to Equity | -14.84 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Heat Biologics Inc
39 employees
CEO: Jeffrey Wolf Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system. The company's gp96 platform is designed to activate immune responses against cancer or infectious diseases. The C...